Biobanking and tissue procurement
Freezers full of consented tumour samples with matched clinical data, which every biomarker and drug programme depends on.
Academic biobanks (MD Anderson, Mayo, UK Biobank for germline, Karolinska, Hartwig for WGS), commercial procurement (Discovery Life Sciences, Indivumed, BioIVT, Precision for Medicine, iSpecimen marketplace), and living biobanks of organoids and PDX (Hubrecht Organoid Technology, Champions Oncology, HCMI) supply tissue, blood, and models for target validation and diagnostic development. Consent breadth, annotation depth, and pre-analytic standardisation determine value.
How it works
Consented collection at surgery or biopsy, controlled fixation or snap-freezing, LIMS tracking, and linked de-identified clinical follow-up.
- Enables retrospective biomarker validation
- Living biobanks allow functional testing
- Consent and governance
- Pre-analytic variability
- Under-representation of many populations
Latest papers
topQuery for this technology: (TITLE:"Biobanking and tissue procurement" OR ABSTRACT:"Biobanking and tissue procurement") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Biobanking and tissue procurement, not a curated reading list.